Australia · Delayed Price · Currency is AUD AdAlta Earnings Call Transcripts
Fiscal Year 2026
-
A new CAR-T cell therapy for mesothelioma, BZDS1901, has been in-licensed and will undergo Phase I trials in Australia, targeting a $4.2 billion market. Early clinical data show strong efficacy, and the program is structured for capital efficiency and rapid value creation.
Fiscal Year 2025
-
A new East-to-West cell therapy strategy is driving growth, with three solid tumor assets under negotiation and a capital-light, scalable business model. AD-214 and WD-34 remain available for partnering, while financing efforts focus on advancing clinical-stage assets.
-
Two-pronged strategy focuses on scaling cell therapy for solid cancers via Asian partnerships and advancing AD-214 for fibrotic diseases through licensing or co-investment. Pipeline progress and leadership expansion position for transaction-driven growth in 2025.